Molecular basis for the role of Glucokinase regulatory protein as the allosteric switch for Glucokinase

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 25, 2013, Pages 10171-10176

  Choi, Jung Min ^a   Seo, Moon Hyeong ^a   Kyeong, Hyun Ho ^a   Kim, Eunkyung ^a   Kim, Hak Sung ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Conformational restriction; Hexokinase; Sigmoidicity; Type 2 diabetes

Indexed keywords

FRUCTOSE 6 PHOSPHATE; GLUCOKINASE; GLUCOKINASE REGULATORY PROTEIN; GLUCOSE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYDROPHOBICITY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; REGULATORY MECHANISM;

HEXOKINASE; SIGMOIDICITY I CONFORMATIONAL RESTRICTION; TYPE 2 DIABETES;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALLOSTERIC REGULATION; ANIMALS; BLOOD GLUCOSE; CARRIER PROTEINS; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; GLUCOKINASE; HUMANS; LIVER; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS; XENOPUS PROTEINS;

EID: 84879319811     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1300457110     Document Type: Article

References (38)

1. Cornish-Bowden A, Cardenas ML (2004) Glucokinase: A monomeric enzyme with positive cooperativity. Frontiers in Diabetes, eds Matschinsky FM, Magnuson MA (Karger, Basel), Vol 16, pp 125-134.
2. Iynedjian PB, Möbius G, Seitz HJ, Wollheim CB, Renold AE (1986) Tissue-specific expression of glucokinase: Identification of the gene product in liver and pancreatic islets. Proc Natl Acad Sci USA 83(7):1998-2001.
3. Agius L (2008) Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 414(1):1-18.
4. Matschinsky FM, et al. (1993) Glucokinase as pancreatic β cell glucose sensor and diabetes gene. J Clin Invest 92(5):2092-2098.
5. Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8(5):399-416.
6. Vionnet N, et al. (1992) Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 356(6371):721-722.
7. Grimsby J, et al. (2003) Allosteric activators of glucokinase: Potential role in diabetes therapy. Science 301(5631):370-373.
8. Matschinsky FM, et al. (2011) Research and development of glucokinase activators for diabetes therapy: Theoretical and practical aspects. Handbook of Experimental Pharmacology, eds Schwanstecher M (Springer, Berlin), Vol 203, pp 357-401.
9. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y (2004) Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12(3):429-438.
10. Nordlie RC, Foster JD, Lange AJ (1999) Regulation of glucose production by the liver. Annu Rev Nutr 19:379-406.
11. Van Schaftingen E (1989) A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate. Eur J Biochem 179(1):179-184.
12. Vandercammen A, Van Schaftingen E (1993) Species and tissue distribution of the regulatory protein of glucokinase. Biochem J 294(pt 2):551-556.
13. Brown KS, Kalinowski SS, Megill JR, Durham SK, Mookhtiar KA (1997) Glucokinase regulatory protein may interact with glucokinase in the hepatocyte nucleus. Diabetes 46(2):179-186.
14. de la Iglesia N, Veiga-da-Cunha M, Van Schaftingen E, Guinovart JJ, Ferrer JC (1999) Glucokinase regulatory protein is essential for the proper subcellular localisation of liver glucokinase. FEBS Lett 456(2):332-338.
15. Toyoda Y, et al. (1994) Evidence for glucokinase translocation by glucose in rat hepatocytes. Biochem Biophys Res Commun 204(1):252-256.
16. Detheux M, Vandercammen A, Van Schaftingen E (1991) Effectors of the regulatory protein acting on liver glucokinase: A kinetic investigation. Eur J Biochem 200(2):553-561.
17. Futamura M, et al. (2006) An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 281(49):37668-37674.
18. Anderka O, et al. (2008) Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: Impact of physiological and pharmacological effectors. J Biol Chem 283(46):31333-31340.
19. Teplyakov A, Obmolova G, Badet-Denisot MA, Badet B, Polikarpov I (1998) Involvement of the C terminus in intramolecular nitrogen channeling in glucosamine 6-phosphate synthase: Evidence from a 1.6 A crystal structure of the isomerase domain. Structure 6(8):1047-1055.
20. Veiga-da-Cunha M, Sokolova T, Opperdoes FR, Van Schaftingen E (2009) Evolution of vertebrate glucokinase regulatory protein from a bacterial N-acetylmuramate 6-phosphate etherase. Biochem J 423(3):323-332.
21. Veiga-da-Cunha M, Van Schaftingen E (2002) Identification of fructose 6-phosphateand fructose 1-phosphate-binding residues in the regulatory protein of glucokinase. J Biol Chem 277(10):8466-8473.
22. Veiga-da-Cunha M, Courtois S, Michel A, Gosselain E, Van Schaftingen E (1996) Amino acid conservation in animal glucokinases. Identification of residues implicated in the interaction with the regulatory protein. J Biol Chem 271(11):6292-6297.
23. Zorn JA, Wells JA (2010) Turning enzymes ON with small molecules. Nat Chem Biol 6(3):179-188.
24. Veiga-Da-Cunha M, Detheux M, Watelet N, Van Schaftingen E (1994) Cloning and expression of a Xenopus liver cDNA encoding a fructose-phosphate-insensitive regulatory protein of glucokinase. Eur J Biochem 225(1):43-51.
25. Agius L (1998) The physiological role of glucokinase binding and translocation in hepatocytes. Adv Enzyme Regul 38:303-331.
26. Vandercammen A, Van Schaftingen E (1991) Competitive inhibition of liver glucokinase by its regulatory protein. Eur J Biochem 200(2):545-551.
27. Goodey NM, Benkovic SJ (2008) Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol 4(8):474-482.
28. Farrelly D, et al. (1999) Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: A sequestration mechanism in metabolic regulation. Proc Natl Acad Sci USA 96(25):14511-14516.
29. Bjørkhaug L, Molnes J, Søvik O, Njølstad PR, Flatmark T (2007) Allosteric activation of human glucokinase by free polyubiquitin chains and its ubiquitin-dependent cotranslational proteasomal degradation. J Biol Chem 282(31):22757-22764.
30. Olson AL, Pessin JE (1996) Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 16:235-256.
31. Shiota C, Coffey J, Grimsby J, Grippo JF, Magnuson MA (1999) Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase. J Biol Chem 274(52):37125-37130.
32. Boyd ME, Albright EB, Foster DW, McGarry JD (1981) In vitro reversal of the fasting state of liver metabolism in the rat. Reevaluation of the roles of insulin and glucose. J Clin Invest 68(1):142-152.
33. Shiota M, et al. (2002) Inclusion of low amounts of fructose with an intraduodenal glucose load markedly reduces postprandial hyperglycemia and hyperinsulinemia in the conscious dog. Diabetes 51(2):469-478.
34. Hallfrisch J, et al. (1983) Effects of dietary fructose on plasma glucose and hormone responses in normal and hyperinsulinemic men. J Nutr 113(9):1819-1826.
35. Hawkins M, et al. (2002) Fructose improves the ability of hyperglycemia per se to regulate glucose production in type 2 diabetes. Diabetes 51(3):606-614.
36. Pfefferkorn JA, et al. (2011) Designing glucokinase activators with reduced hypoglycemia risk: discovery of N, N-dimethyl-5-(2-methyl-6-((5- methylpyrazin-2-yl) - carbamoyl) benzofuran-4-yloxy) pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. Med Chem Commun 2:828-839.
37. Bebernitz GR, et al. (2009) Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 52(19):6142-6152.
38. Pfefferkorn JA, et al. (2012) Discovery of (S)-6-(3-cyclopentyl-2-(4- (trifluoromethyl) - 1H-imidazol-1-yl) propanamido) nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 55(3):1318-1333. Future Planning